Wells Fargo & Company Esperion Therapeutics, Inc. Transaction History
Wells Fargo & Company
- $410 Billion
- Q1 2024
A detailed history of Wells Fargo & Company transactions in Esperion Therapeutics, Inc. stock. As of the latest transaction made, Wells Fargo & Company holds 27,807 shares of ESPR stock, worth $67,014. This represents 0.0% of its overall portfolio holdings.
Number of Shares
27,807
Previous 3,341
732.3%
Holding current value
$67,014
Previous $9,000
722.22%
% of portfolio
0.0%
Previous 0.0%
Shares
17 transactions
Others Institutions Holding ESPR
# of Institutions
176Shares Held
125MCall Options Held
2.07MPut Options Held
1.01M-
Orbimed Advisors LLC San Diego, CA13.7MShares$33 Million0.83% of portfolio
-
Bellevue Group Ag Kuesnacht, V89.94MShares$24 Million0.42% of portfolio
-
Wasatch Advisors Inc Salt Lake City, UT9.13MShares$22 Million0.13% of portfolio
-
Vanguard Group Inc Valley Forge, PA8.83MShares$21.3 Million0.0% of portfolio
-
Great Point Partners LLC Greenwich, CT8MShares$19.3 Million5.25% of portfolio
About Esperion Therapeutics, Inc.
- Ticker ESPR
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 66,551,600
- Market Cap $160M
- Description
- Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascul...